Restructure Information
On September 15, 2019, Purdue announced a preliminary agreement to settle the massive opioid litigation facing the Company. To implement this settlement and secure a final resolution of all pending litigation, Purdue and its subsidiaries voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code.
If you believe you have a claim against Purdue or any of its subsidiaries, please click “Read More Here” below for further information about the Proof of Claim process. JUNE 30, 2020 is the “Bar Date” – THE DEADLINE for every person or entity to submit a Proof of Claim.
Our Commitment to Safety as we Navigate Coronavirus
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.
With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.
About Us
Imbrium Therapeutics is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapies to treat cancer, pain and disorders of the central nervous system.
Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@imbriumthera.com .
When you access any of our websites, related other parities’ websites, mobile applications, or any electronic service, we may use cookies and other technologies to automatically collect information regarding you and your device to assess user activity and preferences. We may also use third-party analytic tools to assist with the collection of information including, but not limited to, Google Analytics. By using this site, you agree to our use of these technologies in accordance with our Privacy Policy.Ok
